Tralokinumab improves patient-reported outcomes for atopic dermatitis

Tralokinumab led to early and clinically meaningful improvements in patient-reported outcomes for moderate to severe atopic dermatitis compared with placebo, according to a study published in Annals of Allergy, Asthma & Immunology.
“These patient-reported outcomes include itch, sleep, quality of life and mental health,” Weily Soong, MD, chief medical officer at AllerVie Health in Birmingham, Alabama, told Healio. “This also is the first time a study has looked at [interleukin]-13 and its role in these patient-reported outcomes.”
As a fully human IgG4 monoclonal

Tralokinumab led to early and clinically meaningful improvements in patient-reported outcomes for moderate to severe atopic dermatitis compared with placebo, according to a study published in Annals of Allergy, Asthma & Immunology.
“These patient-reported outcomes include itch, sleep, quality of life and mental health,” Weily Soong, MD, chief medical officer at AllerVie Health in Birmingham, Alabama, told Healio. “This also is the first time a study has looked at [interleukin]-13 and its role in these patient-reported outcomes.”
As a fully human IgG4 monoclonal